Investors in NVIDIA (NASDAQ:NVDA) have had a lot to celebrate. The company’s graphics processing unit (GPU) remains the gold standard among hardcore and casual gamers alike, and the advent of cloud computing and artificial intelligence (AI) have created vast new markets for NVIDIA’s products.
These developments have led to massive growth, with revenue from the last fiscal year nearly doubling compared to just two years ago. The stock price has followed the financial results, up more than 81% — four times the return of the S&P 500. The company will need to produce blockbuster earnings to keep that trend going.
NVIDIA is scheduled to reports its financial results for its first quarter on Thursday, May 10, after the market closes. Here are some of the things investors should look for.
What will the quarter hold for NVIDIA investors? Image source: NVIDIA.
Best Financial Stocks To Watch For 2019: AmeriGas Partners, L.P.(APU)
- [By Motley Fool Transcribers]
Amerigas Partners LP (NYSE:APU)Q1 2019 Earnings Conference CallFeb. 06, 2019, 9:00 a.m. ET
Prepared Remarks Questions and Answers Call Participants
- [By John Bromels]
If you’re like me, you probably use branded propane tanks from AmeriGas Partners (NYSE:APU) or Blue Rhino, which is owned by Ferrellgas Partners, L.P. (NYSE:FGP) (Full disclosure: Propane is propane. I use AmeriGas because it’s what the local convenience store sells.) Either one will get your burgers cooked, but which one will keep your portfolio cooking along?
- [By John Bromels]
I use propane tanks from AmeriGas Partners (NYSE:APU) because that’s what my local convenience store sells, but many outdoor cooks use Blue Rhino, which is owned by Ferrellgas Partners, L.P. (NYSE:FGP). There’s no difference between them when it comes to getting your burgers browned or your ribs crispy — propane is propane, after all, regardless of who’s selling it — but there are big differences in the two companies from an investor’s standpoint.
- [By Maxx Chatsko]
Investors seeking income from energy stocks will find it difficult to match the impressive yields of Ferrellgas Partners LP (NYSE:FGP) and AmeriGas Partners (NYSE:APU), which sit at 11.9% and 9%, respectively. However, this is a textbook case of higher yields representing higher levels of risk.
Best Financial Stocks To Watch For 2019: Ligand Pharmaceuticals Incorporated(LGND)
- [By Cory Renauer]
Finding a partner for VK5211 or VK2809 will be a bit more challenging than usual because Viking doesn’t own the drugs outright. Viking licensed them from Ligand Pharmaceuticals (NASDAQ:LGND) a few years ago and owes Ligand single-digit royalties on any sales either drug might generate. Coincidentally, Madrigal entered a similar agreement with Roche to get its hands on MGL-3196 back in 2008.
- [By Keith Speights]
Which companies that are relatively small right now could become the big biotechs of the future? Here’s why I think that Editas Medicine (NASDAQ:EDIT), Ligand Pharmaceuticals (NASDAQ:LGND), and Exelixis (NASDAQ:EXEL) could be monster biotech stocks in the making.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Ligand Pharmaceuticals (LGND)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
These are some of the news stories that may have effected Accern Sentiment’s scoring:
Get Ligand Pharmaceuticals alerts:
Ligand Pharmaceuticals (LGND) Insider Sells $1,488,722.03 in Stock (americanbankingnews.com) Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down (finance.yahoo.com) Ligand Pharmaceuticals (LGND) Upgraded to A- by TheStreet (americanbankingnews.com) Ligand to Participate in Upcoming Investor Conferences (finance.yahoo.com) Ligand Pharmaceuticals Shows Rising Price Performance With Jump To 87 RS Rating (investors.com)
A number of research firms recently issued reports on LGND. TheStreet raised Ligand Pharmaceuticals from a “c+” rating to an “a-” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $170.00 price objective on shares of Ligand Pharmaceuticals in a research report on Friday, February 2nd. Zacks Investment Research raised Ligand Pharmaceuticals from a “hold” rating to a “buy” rating and set a $171.00 price objective for the company in a research report on Wednesday, February 28th. BidaskClub cut Ligand Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, Roth Capital lifted their price objective on Ligand Pharmaceuticals from $158.00 to $171.00 and gave the company a “buy” rating in a research report on Monday, February 26th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $161.00.
- [By Reuben Gregg Brewer, Keith Speights, and Brian Stoffel]
That’s certainly the case with surprisingly diversified biotech company Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), out-of-favor outlet mall owner Tanger Factory Outlet Centers, Inc. (NYSE:SKT), and expanding software-maker New Relic, Inc. (NYSE:NEWR). Take the time for a deep dive, and you might find that one of these three mid-cap stocks is just right for your portfolio today.
- [By Jon C. Ogg]
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was maintained as Buy at Argus, but the firm lowered its target to $150 from $200. The independent research firm noted that recent weakness offers a buying opportunity as the company is believed to be on track to post solid earnings growth over the next several years. Ligand closed up 1.5% at $119.76 on Tuesday, in a 52-week range of $98.56 to $278.62.
Best Financial Stocks To Watch For 2019: Statoil ASA(STO)
- [By Shane Hupp]
Statoil (NYSE: STO) and Delek US (NYSE:DK) are both oils/energy companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.
- [By Tyler Crowe]
Anyone that has watched oil prices tick up recently has probably expected oil producers to report some impressive earnings results this past quarter, and Statoil (NYSE:STO) did just that with a 21% boost to the bottom line. At the same time, management is using all of its additional cash to do some wheeling and dealing that should help boost its growth possibilities in the nearer term.
- [By Matthew DiLallo]
Another highlight in April was that Shell gave the green light to the Vito project, which is a joint venture with Statoil (NYSE:STO) in the Gulf of Mexico. Shell and Statoil were able to cut that project’s cost estimate by 70% from the original design so that it’s now profitable at $35 a barrel. The partners expect the project to produce 100,000 BOE/D of low-cost oil and gas when it comes online in 2021.